Preferred Label : empagliflozin;
MeSH note : inhibits sodium glucose cotransporter-2 (SGLT-2); structure in first source;
CISMeF synonym : BI 10773;
MeSH synonym : 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene;
MeSH hyponym : BI10773; BI-10773;
Is substance : O;
UNII : HDC1R2M35U;
InChIKey : OBWASQILIWPZMG-QZMOQZSNSA-N;
Origin ID : C570240;
UMLS CUI : C3490348;
ATC code(s)
CISMeF manual mappings
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also (suggested by CISMeF)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3497011/fr/jardiance-empagliflozine-maladie-renale-chronique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
empagliflozin
drug therapy, combination
administration, oral
Sodium-Glucose Transporter 2 Inhibitors
chronic kidney diseases
evaluation of the transparency committee
empagliflozin
---
https://www.has-sante.fr/jcms/p_3518844/fr/jardiance-empagliflozine-diabete-de-type-2-chez-les-enfants-ages-de-10-ans-et-plus
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Sodium-Glucose Transporter 2 Inhibitors
empagliflozin
administration, oral
drug therapy, combination
evaluation of the transparency committee
child
empagliflozin
diabetes mellitus, type 2
---
https://www.usherbrooke.ca/baladocritique/archives/episode-53-etude-empa-kidney
2023
France
sound
Chronic renal failure
renal insufficiency, chronic
empagliflozin
episode of
empagliflozin
data collection
persons
chronic renal failure syndrome, nos
Renal failure
---
https://www.has-sante.fr/jcms/p_3343465/fr/jardiance-empagliflozine-insuffisance-cardiaque
https://has-sante.fr/jcms/p_3343475/fr/decision-n-2022-0310/dp/sem-du-3-juin-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-jardiance
2023
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
guidelines for drug use
heart failure
empagliflozin
---
https://www.has-sante.fr/jcms/p_3352200/fr/jardiance-empagliflozine-insuffisance-cardiaque-chronique-symptomatique
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
empagliflozin
chronic disease
heart failure
Chronic heart failure (disorder)
evaluation of the transparency committee
---
https://minerva-ebp.be/FR/Analysis/774
2022
Belgium
critical appraisal or critical reading
Diabetes mellitus type 2
semaglutide
administrative personnel
organization and administration
weight loss
decreased body weight
weight loss
empagliflozin
diabetes mellitus, type 2
semaglutide
Administration
has patient
administration
patients
administrators
blood glucose
empagliflozin
disease
diabetes non-insulin dependent
---
https://www.has-sante.fr/jcms/p_3315443/fr/jardiance-icc-empagliflozine
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
heart failure
chronic disease
Chronic heart failure (disorder)
adult
evaluation of the transparency committee
empagliflozin
---
https://www.has-sante.fr/jcms/p_3224377/fr/medicaments-du-diabete-de-type-2-la-has-actualise-son-evaluation-des-gliflozines
2021
false
false
false
France
French
drug evaluation
Sodium-Glucose Transporter 2 Inhibitors
diabetes mellitus, type 2
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
Canagliflozin
empagliflozin
empagliflozin
Canagliflozin
dapagliflozin
treatment outcome
diabetic cardiomyopathies
diabetic nephropathies
risk
continuity of patient care
drug monitoring
dapagliflozin
---
https://ansm.sante.fr/actualites/diabete-maladie-renale-chronique-insuffisance-cardiaque-prescription-initiale-de-dapagliflozine-et-dempagliflozine-etendue-a-tous-les-medecins
2021
false
false
false
France
French
drug information
dapagliflozin
empagliflozin
dapagliflozin
---
https://www.has-sante.fr/jcms/p_3218341/fr/synjardy
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
metformin
Metformin Hydrochloride
empagliflozin
metformin and empagliflozin
hypoglycemic agents
Sodium-Glucose Transporter 2 Inhibitors
administration, oral
diabetes mellitus, type 2
guidelines for drug use
evaluation of the transparency committee
benzhydryl compounds
glucosides
---
https://www.has-sante.fr/jcms/p_3218344/fr/jardiance
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
Sodium-Glucose Transporter 2 Inhibitors
empagliflozin
administration, oral
Product containing precisely empagliflozin 10 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing precisely empagliflozin 25 milligram/1 each conventional release
oral tablet (clinical drug)
adult
diabetes mellitus, type 2
drug therapy, combination
sulfonylurea compounds
metformin
evaluation of the transparency committee
Jardiance
empagliflozin
benzhydryl compounds
glucosides
---
https://smf.swisshealthweb.ch/fr/article/doi/fms.2019.08247/
https://doi.org/10.4414/fms.2019.08247
2019
false
false
false
Switzerland
case reports
Sodium-Glucose Transporter 2 Inhibitors
journal article
diabetes with ketoacidosis
empagliflozin
diabetes mellitus
ketosis
benzhydryl compounds
glucosides
---
https://www.has-sante.fr/portail/jcms/c_2906422/fr/jardiance
https://www.has-sante.fr/portail/jcms/c_2906422/fr/jardiance-empagliflozine-antidiabetique-oral
2019
false
true
false
false
France
treatment outcome
empagliflozin
empagliflozin
hypoglycemic agents
hypoglycemic agents
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2 Inhibitors
empagliflozin
administration, oral
adult
diabetes mellitus, type 2
drug therapy, combination
cardiovascular diseases
guidelines for drug use
evaluation of the transparency committee
Jardiance
benzhydryl compounds
glucosides
benzhydryl compounds
glucosides
---
https://rmlg.uliege.be/article/2974
2018
false
false
false
false
Belgium
French
journal article
diabetes mellitus, type 2
cardiovascular diseases
hypoglycemic agents
empagliflozin
treatment outcome
empagliflozin
Sodium-Glucose transporter 2
comparative effectiveness research
Liraglutide
liraglutide
Glucagon-Like Peptide-1 Receptor
incretins
case reports
prognosis
cardiovascular diseases
drug therapy, combination
diabetes mellitus, type 2
renal insufficiency, chronic
belgium
insurance, health, reimbursement
Clinical Decision-Making
risk factors
Sodium-Glucose Transporter 2 Inhibitors
benzhydryl compounds
glucosides
---
https://www.revmed.ch/RMS/2017/RMS-N-565/Acidocetose-euglycemique-une-complication-des-inhibiteurs-du-SGLT2
2018
false
false
false
Switzerland
French
administration, oral
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Product containing sodium glucose cotransporter subtype 2 inhibitor (product)
SGLT2 Inhibitor
Sodium-Glucose transporter 2
Canagliflozin
hypoglycemic agents
empagliflozin
dapagliflozin
ketosis
journal article
practice guidelines as topic
precipitating factors
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
benzhydryl compounds
glucosides
---
https://www.has-sante.fr/jcms/c_2722414/fr/jardiance-empagliflozine-antidiabetique-oral
2017
false
false
false
France
French
evaluation of the transparency committee
empagliflozin
empagliflozin
administration, oral
treatment outcome
insurance, health, reimbursement
diabetes mellitus, type 2
drug therapy, combination
metformin
insulin
sulfonylurea compounds
adult
SLC5A2 protein, human
empagliflozin
guidelines for drug use
Sodium-Glucose Transporter 2 Inhibitors
benzhydryl compounds
glucosides
benzhydryl compounds
glucosides
Sodium-Glucose transporter 2
---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/1146
2017
false
false
false
false
Canada
French
journal article
empagliflozin
empagliflozin
diabetes mellitus, type 2
hypoglycemic agents
hypoglycemic agents
cardiovascular diseases
cardiovascular diseases
cardiovascular diseases
multicenter studies as topic
risk factors
hospitalization
critical appraisal or critical reading
heart failure
randomized controlled trials as topic
Sodium-Glucose transporter 2
Sodium-Glucose Transporter 2 Inhibitors
empagliflozin
benzhydryl compounds
glucosides
benzhydryl compounds
glucosides
---
https://www.ema.europa.eu/medicines/human/EPAR/Glyxambi
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
Linagliptin
empagliflozin
drug approval
europe
treatment outcome
pregnancy
breast feeding
hypoglycemic agents
hypoglycemic agents
adult
diabetes mellitus, type 2
product surveillance, postmarketing
linagliptin and empagliflozin
administration, oral
Sodium-Glucose transporter 2
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
drug evaluation, preclinical
Product containing empagliflozin and linagliptin (medicinal product)
Sodium-Glucose Transporter 2 Inhibitors
Linagliptin
empagliflozin
benzhydryl compounds
glucosides
benzhydryl compounds
glucosides
---
Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin)
- Assessing the Potential Risk of Bone-Related Side Effects
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/sglt2-3-fra.php
2016
false
false
false
Canada
French
English
Canagliflozin
hypoglycemic agents
dapagliflozin
Sodium-Glucose transporter 2
SGLT2 Inhibitor
risk assessment
drug evaluation
empagliflozin
adult
diabetes mellitus, type 2
fractures, bone
bone demineralization, pathologic
bone and bones
pharmacovigilance note
product surveillance, postmarketing
canada
dapagliflozin
canagliflozin
empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
benzhydryl compounds
glucosides
---
https://www.revmed.ch/RMS/2016/RMS-N-527/Combinaison-gliptine-gliflozine-dans-le-traitement-du-diabete-de-type-2
2016
false
false
false
Switzerland
French
journal article
diabetes mellitus, type 2
drug combinations
hypoglycemic agents
dipeptidyl-peptidase iv inhibitors
SGLT2 Inhibitor
treatment outcome
saxagliptin and dapagliflozin
dapagliflozin
saxagliptin
Linagliptin
linagliptin and empagliflozin
empagliflozin
Product containing empagliflozin and linagliptin (medicinal product)
administration, oral
Sodium-Glucose transporter 2
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
dipeptides
adamantane
adamantane
benzhydryl compounds
glucosides
---
SGLT2 inhibitors
https://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2016-12-fra.php#sglt2
2016
false
false
false
Canada
French
English
drug evaluation
SGLT2 Inhibitor
Sodium-Glucose transporter 2
Canagliflozin
hypoglycemic agents
risk assessment
dapagliflozin
empagliflozin
diabetes mellitus, type 2
fractures, bone
bone demineralization, pathologic
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
glucosides
benzhydryl compounds
---
New antidiabetic medications : at the dawn of a revolution ? New therapeutic options
for type 2 diabetes are challenged for cardiovascular disease prevention
http://www.amub-ulb.be/revue-medicale-bruxelles/article/nouveaux-antidiabetiques-a-laube-dune-revolution-l-1219
2016
false
false
false
Belgium
French
journal article
hypoglycemic agents
diabetes mellitus, type 2
cardiovascular diseases
empagliflozin
Liraglutide
treatment outcome
myocardial infarction
stroke
cardiovascular diseases
administration, oral
incretins
dipeptidyl-peptidase iv inhibitors
SGLT2 Inhibitor
Sodium-Glucose transporter 2
liraglutide
empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
benzhydryl compounds
glucosides
---
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58404a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
Sodium-Glucose transporter 2
SGLT2 Inhibitor
Canagliflozin
hypoglycemic agents
dapagliflozin
metformin and dapagliflozin
drug combinations
metformin
empagliflozin
diabetic ketoacidosis
guidelines for drug use
diabetes mellitus, type 2
risk factors
dapagliflozin
canagliflozin
empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
glucosides
benzhydryl compounds
---
Summary Basis of Decision (SBD) for Jardiance
Empagliflozin, 10 mg and 25 mg, tablets, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00257
2015
false
false
false
Canada
French
English
treatment outcome
summary of product characteristics
empagliflozin
empagliflozin
drug approval
diabetes mellitus, type 2
adult
administration, oral
SLC5A2 protein, human
drug monitoring
product surveillance, postmarketing
aged
clinical trials as topic
drug evaluation, preclinical
canada
risk assessment
drug evaluation
empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
benzhydryl compounds
glucosides
benzhydryl compounds
glucosides
Sodium-Glucose transporter 2
---
https://www.ema.europa.eu/medicines/human/EPAR/Synjardy
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
metformin
metformin
drug combinations
drug approval
europe
hypoglycemic agents
hypoglycemic agents
empagliflozin
empagliflozin
diabetes mellitus, type 2
metformin and empagliflozin
product surveillance, postmarketing
adult
administration, oral
SLC5A2 protein, human
SGLT2 Inhibitor
SGLT2 Inhibitor
drug interactions
pregnancy
breast feeding
aged
drug evaluation, preclinical
Product containing empagliflozin and metformin (medicinal product)
Sodium-Glucose Transporter 2 Inhibitors
benzhydryl compounds
glucosides
benzhydryl compounds
glucosides
Sodium-Glucose transporter 2
---
https://smf.swisshealthweb.ch/fr/article/doi/fms.2015.02513/
2015
false
false
false
Switzerland
French
journal article
hypoglycemic agents
administration, oral
diabetes mellitus, type 2
diabetes mellitus, type 2
risk factors
cardiovascular diseases
cardiovascular diseases
empagliflozin
SLC5A2 protein, human
Glycated Hemoglobin
cardiovascular diseases
adult
treatment outcome
randomized controlled trials as topic
empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
benzhydryl compounds
glucosides
Sodium-Glucose transporter 2
---
http://www.has-sante.fr/portail/jcms/c_2003853/fr/jardiance
http://www.has-sante.fr/portail/jcms/c_2003853/fr/jardiance-empagliflozine-antidiabetique-oral
2014
false
false
false
France
French
evaluation of the transparency committee
empagliflozin
empagliflozin
guidelines for drug use
administration, oral
treatment outcome
insurance, health, reimbursement
diabetes mellitus, type 2
drug therapy, combination
metformin
insulin
sulfonylurea compounds
adult
SLC5A2 protein, human
empagliflozin
Product containing precisely empagliflozin 10 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing precisely empagliflozin 25 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing empagliflozin (medicinal product)
Sodium-Glucose Transporter 2 Inhibitors
benzhydryl compounds
glucosides
benzhydryl compounds
glucosides
Sodium-Glucose transporter 2
---
https://www.ema.europa.eu/medicines/human/EPAR/Jardiance
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
empagliflozin
empagliflozin
drug approval
europe
diabetes mellitus, type 2
adult
administration, oral
SLC5A2 protein, human
drug monitoring
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
clinical trials as topic
drug evaluation, preclinical
empagliflozin
Product containing precisely empagliflozin 10 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing precisely empagliflozin 25 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing empagliflozin (medicinal product)
Sodium-Glucose Transporter 2 Inhibitors
benzhydryl compounds
glucosides
benzhydryl compounds
glucosides
Sodium-Glucose transporter 2
---